Bioinformatic Analysis of Genetic Factors from Human Blood Samples and Postmortem Brains in Parkinson’s Disease

Figure 6

A case-control study was used to validate peripheral blood PD markers. (a) The mRNA expression levels of G6PD, MDH2, GRID2, RIPK2, CUL4B, BCL6, MRPS31, GPI, and MAP 2 K1 were studied using qRT-PCR in a total of 40 PD patients and 21 healthy controls. (b) The mRNA expression levels of MAPK, ELAVL1, RAB14, KLF9, ARF1, ARFGAP1, ATG7, ABCA7, SFT2D2, E2F2, MAPK7, and UHRF1 were evaluated by qRT-PCR. (c–f) The mRNA expression of G6PD, MDH2, GRID2, RIPK2, CUL4B, BCL6, MRPS31, GPI, MAP 2 K1, MAPK, ELAVL1, RAB14, KLF9, ARF1, ARFGAP1, ATG7, ABCA7, SFT2D2, E2F2, MAPK7, and UHRF1 were compared between healthy control and PD patients. (g) The mRNA levels of KLF9, ARF1, and ABCA7 were shown in a time-dependent matter.

(a)

(b)

(c)

(d)

(e)

(f)

(g)